Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
University of Florida
714
mi
from 43215
Gainesville, FL
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
University of Florida
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
University of Louisville
188
mi
from 43215
Louisville, KY
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
University of Louisville
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
Premier Medical Group of the Hudson Valley
490
mi
from 43215
Poughkeepsie, NY
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
Premier Medical Group of the Hudson Valley
490
mi
from 43215
Poughkeepsie, NY
Click here to add this to my saved trials
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
Options Health Research
752
mi
from 43215
Tulsa, OK
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
Options Health Research
752
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
Gastro One
501
mi
from 43215
Germantown, TN
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
Gastro One
501
mi
from 43215
Germantown, TN
Click here to add this to my saved trials
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  4/20/2018
Local Institution
4608
mi
from 43215
Wien,
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 4/20/2018
Local Institution
4608
mi
from 43215
Wien,
Click here to add this to my saved trials
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers
Status: Enrolling
Updated:  4/20/2018
Pulmonary Associates Clinical Trials (PACT)
1662
mi
from 43215
Phoenix, AZ
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers
Status: Enrolling
Updated: 4/20/2018
Pulmonary Associates Clinical Trials (PACT)
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1949
mi
from 43215
Carlsbad, CA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1949
mi
from 43215
Carlsbad, CA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
2091
mi
from 43215
Castro Valley, CA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
2091
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
2031
mi
from 43215
Fair Oaks, CA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
2031
mi
from 43215
Fair Oaks, CA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1976
mi
from 43215
Sylmar, CA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1976
mi
from 43215
Sylmar, CA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
328
mi
from 43215
Washington,
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1612
mi
from 43215
Missoula, MT
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1612
mi
from 43215
Missoula, MT
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
2057
mi
from 43215
Eugene, OR
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
2057
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
251
mi
from 43215
Roanoke, VA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
251
mi
from 43215
Roanoke, VA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
437
mi
from 43215
Virginia Beach, VA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
437
mi
from 43215
Virginia Beach, VA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
279
mi
from 43215
Hamilton,
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
279
mi
from 43215
Hamilton,
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
274
mi
from 43215
North Chicago, IL
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
274
mi
from 43215
North Chicago, IL
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1767
mi
from 43215
Las Vegas, NV
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1767
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1291
mi
from 43215
McAllen, TX
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1291
mi
from 43215
McAllen, TX
Click here to add this to my saved trials
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K
A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Click here to add this to my saved trials
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Methadone, Buprenorphine and Fetal Development
Status: Enrolling
Updated:  4/24/2018
Center for Addiction and Pregnancy
347
mi
from 43215
Baltimore, MD
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Methadone, Buprenorphine and Fetal Development
Status: Enrolling
Updated: 4/24/2018
Center for Addiction and Pregnancy
347
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Anal Dysplasia in Patients With Inflammatory Bowel Disease
The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  4/24/2018
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Anal Dysplasia in Patients With Inflammatory Bowel Disease
The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 4/24/2018
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Anal Dysplasia in Patients With Inflammatory Bowel Disease
The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  4/24/2018
Stony Brook University Hospital
549
mi
from 43215
Stony Brook, NY
Anal Dysplasia in Patients With Inflammatory Bowel Disease
The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 4/24/2018
Stony Brook University Hospital
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Preferred Research Partners, Inc.
622
mi
from 43215
Little Rock, AR
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Preferred Research Partners, Inc.
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Surinder Singh Saini, M.D., Inc.
1967
mi
from 43215
Newport Beach, CA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Surinder Singh Saini, M.D., Inc.
1967
mi
from 43215
Newport Beach, CA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Inland Empire Liver Foundation
1925
mi
from 43215
Rialto, CA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Inland Empire Liver Foundation
1925
mi
from 43215
Rialto, CA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Iowa Digestive Disease Center
573
mi
from 43215
Clive, IA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Iowa Digestive Disease Center
573
mi
from 43215
Clive, IA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Mercy Medical Center
344
mi
from 43215
Baltimore, MD
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Mercy Medical Center
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Kansas City Research Institute
619
mi
from 43215
Kansas City, MO
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Kansas City Research Institute
619
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Options Health Research
752
mi
from 43215
Tulsa, OK
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Options Health Research
752
mi
from 43215
Tulsa, OK
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
University Gastroenterology
619
mi
from 43215
Providence, RI
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University Gastroenterology
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
ClinSearch, LLC
360
mi
from 43215
Chattanooga, TN
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
ClinSearch, LLC
360
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Texas Clinical Research Institute
927
mi
from 43215
Arlington, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Texas Clinical Research Institute
927
mi
from 43215
Arlington, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Liver Associates of Texas
995
mi
from 43215
Houston, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Liver Associates of Texas
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
American Research Corporation at the Texas Liver Institue
1138
mi
from 43215
San Antonio, TX
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
American Research Corporation at the Texas Liver Institue
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Digestive and Liver Disease Specialists
426
mi
from 43215
Norfolk, VA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Digestive and Liver Disease Specialists
426
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Vanderbilt University Medical Center - Digestive Disease Center
334
mi
from 43215
Nashville, TN
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Vanderbilt University Medical Center - Digestive Disease Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Uf Hepatology Research At Ctrb
714
mi
from 43215
Gainesville, FL
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Uf Hepatology Research At Ctrb
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
University Of Miami Schiff Center For Liver Diseases
992
mi
from 43215
Miami, FL
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University Of Miami Schiff Center For Liver Diseases
992
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Florida Hospital Orlando Transplant Institute
792
mi
from 43215
Orlando, FL
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Florida Hospital Orlando Transplant Institute
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
Gastrointestinal Specialists of Georgia
425
mi
from 43215
Marietta, GA
Click here to add this to my saved trials
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated:  4/26/2018
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status: Enrolling
Updated: 4/26/2018
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials